Genomic Health (GHDX) Downgraded by William Blair

William Blair lowered shares of Genomic Health (NASDAQ:GHDX) from an outperform rating to a market perform rating in a research note published on Wednesday morning, MarketBeat Ratings reports.

GHDX has been the topic of several other research reports. Zacks Investment Research raised shares of Genomic Health from a sell rating to a hold rating in a research report on Friday, October 13th. Cowen reaffirmed a hold rating and set a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. Canaccord Genuity reaffirmed a buy rating and set a $39.00 price objective on shares of Genomic Health in a research report on Wednesday, November 15th. Jefferies Group reaffirmed a hold rating and set a $33.00 price objective on shares of Genomic Health in a research report on Thursday, September 14th. Finally, ValuEngine raised shares of Genomic Health from a sell rating to a hold rating in a research report on Friday, December 15th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $31.57.

Shares of Genomic Health (GHDX) traded down $0.04 on Wednesday, reaching $36.20. 118,476 shares of the company traded hands, compared to its average volume of 235,666. The company has a market capitalization of $1,260.62, a price-to-earnings ratio of -301.67 and a beta of 0.66. Genomic Health has a 52-week low of $26.37 and a 52-week high of $37.50.

In other news, insider Phillip G. Febbo sold 5,334 shares of Genomic Health stock in a transaction that occurred on Tuesday, December 19th. The shares were sold at an average price of $36.99, for a total value of $197,304.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Kimberly J. Popovits sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $31.50, for a total transaction of $630,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 62,713 shares of company stock worth $2,037,926. Insiders own 46.20% of the company’s stock.

Several institutional investors have recently made changes to their positions in GHDX. Vanguard Group Inc. grew its stake in shares of Genomic Health by 6.8% in the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after acquiring an additional 106,452 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after buying an additional 80,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Genomic Health by 26.1% during the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after buying an additional 76,758 shares in the last quarter. Citadel Advisors LLC boosted its stake in Genomic Health by 269.5% during the third quarter. Citadel Advisors LLC now owns 93,803 shares of the medical research company’s stock worth $3,010,000 after buying an additional 68,418 shares in the last quarter. Finally, Cowen Prime Services LLC boosted its stake in Genomic Health by 324.1% during the second quarter. Cowen Prime Services LLC now owns 88,635 shares of the medical research company’s stock worth $2,885,000 after buying an additional 67,735 shares in the last quarter. Institutional investors and hedge funds own 89.61% of the company’s stock.

WARNING: “Genomic Health (GHDX) Downgraded by William Blair” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2017/12/23/genomic-health-ghdx-downgraded-by-william-blair.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit